Eli Lilly Opens Limited Early Access Program for Experimental Obesity Drug Retatrutide

Aug 3, 2026

Eli Lilly has formalized a limited early access program for its experimental obesity drug, retatrutide, following reports of a single-patient compassionate use arrangement. To qualify, patients must be adults with refractory obesity who have failed maximal approved therapies, suffer from at least two life-threatening complications, and cannot join clinical trials. While Phase 3 trials show unprecedented weight loss of up to 28.3%, standard FDA approval is not expected until late 2027 or early 2028, leaving a massive gap that has fueled a dangerous, unregulated online gray market.

Lilly retatrutide expanded access

▪The formalization of Eli Lilly's expanded access program follows media reports that the company had previously granted special compassionate use access to a single, unnamed 79-year-old male patient.
▪Eli Lilly confirmed on August 3, 2026, that it has established a formal expanded access program to provide its experimental obesity drug, retatrutide, to a limited number of eligible patients before receiving FDA approval.

Strict eligibility requirements

▪Patients seeking retatrutide through Eli Lilly's program must have at least two serious or life-threatening obesity-related complications for which they are actively receiving care.
▪To qualify for Eli Lilly's retatrutide expanded access program, a patient must be 18 years of age or older and have refractory obesity despite tolerating the highest approved dose of an existing obesity therapy.
▪Eligible patients for Eli Lilly's retatrutide program must be unable to enroll in any ongoing clinical trial of retatrutide or a comparable investigational drug.

Phase 3 trial results

▪In a Phase 3 trial of adults with severe obesity and established cardiovascular disease, participants on the highest weekly dose of retatrutide achieved an average weight loss of 22.6% over 80 weeks.
▪In the Phase 3 TRIUMPH-1 trial, participants on the highest 12 mg weekly dose of retatrutide achieved an average weight loss of 28.3% over 80 weeks.

Unregulated gray market sales

▪A CBS News investigation documented more than 120 websites and over 50 clinics across the United States actively selling or promoting retatrutide without FDA approval.
▪Human exposures to unregulated retatrutide reported to United States poison control centers averaged 95 monthly cases in the first four months of 2026.

FDA approval timeline

▪The realistic window for FDA approval of retatrutide is late 2027 to early 2028, with standard commercial availability expected in 2028 or later.
▪Eli Lilly plans to submit a Biologics License Application for retatrutide to the FDA in the first quarter of 2027.

Patient safety risks

▪In supervised clinical trials, nausea occurred in 42.4% of participants on the highest dose of retatrutide, and dysesthesia appeared in 12.5% of participants.
▪Unregulated retatrutide products sold online carry risks of contamination with heavy metals, endotoxins, and incorrect peptide sequences.